Physician profile
Sean Olaughlin
NPI 1235505439
$109,624.48
in general payments reported to CMS, 2019-2025
54 companies · $6,861 in 2025
The $6,861 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $55K · 2022: $33K · 2023: $6,911 · 2024: $8,083 · 2025: $6,861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $5,260 · Education: $220 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,225.00 |
| Food and Beverage | $5,260.35 |
| Education | $220.04 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $80,147.84 | 2021-2025 | |
| Amgen INC. | $9,777.27 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $9,770.79 | 2021 | |
| Allergan, INC. | $1,409.80 | 2021 | |
| Ucb, INC. | $1,112.49 | 2021-2025 | Briviact, Rystiggo, Fintepla |
| Lundbeck LLC | $1,027.20 | 2021-2025 | Vyepti, Rexulti |
| Alexion Pharmaceuticals, INC. | $690.35 | 2023-2025 | Ultomiris, Soliris |
| Biogen, INC. | $665.64 | 2021-2025 | Tysabri, Vumerity, Avonex |
| Novartis Pharmaceuticals Corporation | $503.78 | 2021-2023 | |
| Pfizer INC. | $421.73 | 2023-2025 | |
| Sk Life Science, INC. | $354.59 | 2021-2025 | |
| Genzyme Corporation | $336.55 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $321.54 | 2022-2025 | Purified Cortrophin Gel |
| Biohaven Pharmaceutical Holding Company LTD. | $236.71 | 2022 | |
| Lilly USA, LLC | $206.23 | 2021-2024 | Amyvid, Emgality, Kisunla |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $203.09 | 2021-2024 | Ocrevus, Ocrevus Zunovo |
| Amneal Pharmaceuticals LLC | $170.29 | 2021-2023 | Lyvispah |
| Eisai INC. | $153.67 | 2021-2024 | |
| Livanova USA, INC. | $147.21 | 2021-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Tg Therapeutics, INC. | $126.42 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $116.89 | 2021-2023 | |
| Kyowa Kirin, INC. | $111.69 | 2021-2023 | Nourianz |
| Mallinckrodt Hospital Products INC. | $103.56 | 2021-2023 | Acthar |
| Sumitomo Pharma America, INC. | $101.63 | 2023 | Aptiom |
| Teva Pharmaceuticals USA, INC. | $97.75 | 2021-2023 | Austedo |
| Axsome Therapeutics, INC. | $78.30 | 2025 | Symbravo |
| Banner Life Sciences, LLC | $77.37 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $74.68 | 2021-2022 | |
| Emd Serono, INC. | $73.29 | 2022-2023 | Mavenclad |
| Sunovion Pharmaceuticals INC. | $72.84 | 2021-2022 | |
| Csl Behring | $70.88 | 2022-2023 | Hizentra |
| Janssen Pharmaceuticals, INC | $70.61 | 2022 | |
| Insightec,INC | $70.34 | 2023 | Exablate |
| Celgene Corporation | $66.17 | 2022-2023 | Zeposia |
| Neurelis, INC. | $62.81 | 2021-2024 | Valtoco |
| Acorda Therapeutics, INC | $58.23 | 2022-2023 | Inbrija |
| Impel Pharmaceuticals INC. | $56.78 | 2023 | Trudhesa |
| Neurocrine Biosciences, INC. | $50.98 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $49.62 | 2021-2024 | Fycompa |
| Avion Pharmaceuticals | $48.59 | 2022 | |
| Janssen Biotech, INC. | $41.66 | 2025 | |
| Boston Scientific Corporation | $34.71 | 2021-2022 | |
| Argenx US, INC. | $28.86 | 2022 | |
| Novocure INC. | $25.97 | 2024 | Optune |
| Upsher-Smith Laboratories LLC | $24.45 | 2021 | |
| Corium, LLC | $23.80 | 2023 | Adlarity |
| Abbott Laboratories | $23.34 | 2022 | |
| Tersera Therapeutics LLC | $22.33 | 2024 | Quzyttir |
| Astrazeneca Pharmaceuticals LP | $20.99 | 2021 | |
| Tms Neurohealth Centers INC. | $19.82 | 2025 | Tms Neurohealth Centers INC. |
| Mdd US Operations, LLC | $17.10 | 2024 | Gocovri |
| Takeda Pharmaceuticals U.S.A., INC. | $15.56 | 2021 | |
| Collegium Pharmaceutical, INC. | $14.86 | 2022 | |
| Genentech, INC. | $14.83 | 2023 | Ocrevus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Olaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.